Structure-Based Design and Characterization of Axitinib

Kinase Inhibitor Drugs

Volumn , Issue , 2009, Pages 167-201

  Kania, Robert S ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Deep pocket binders amide functional group addition; Indazole series discovery; Structure based design and axitinib characterization

Indexed keywords

EID: 84889814362     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470524961.ch7     Document Type: Chapter

References (66)

1. Abhyankar, V. V., Sharma, S., Trowbridge, R. C., et al. (2008). Axitinib (AG-013736) in combination with FOLFOX and bevacizumab in patients with metastatic solid tumors: a Phase I study. J Clin Oncol. 26 (18S), 206s.
2. Alton, G. R., and Lunney, E. A. (2008). Targeting the unactivated conformations of protein kinases for small molecule drug discovery. Expert Opin Drug Discov. 3 (6), 595-605.
3. Andrews, P. R., Craik, D. J., and Martin, J. L. (1984). Functional group contributions to drug-receptor interactions. J Med Chem. 27 (12), 1648-1657.
4. Bender, S. L., Bhumralkar, D., Collins, M. R., et al. (2001). Synthesis of heteroarylbenzamides and analogs used for inhibiting protein kinases. WO 2001/053274A1.
5. Bender, S. L., Kania, R. S., and McTigue, M. A. (2004). Crystal structure of human VEGFR2 kinase domain-ligand complexes and use of the atomic coordinates in drug discovery. WO 2004/092217 A1.
6. Bergers, G., and Benjamin, L. E. (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3 (6), 401-410.
7. Borgström, P., Hillan, K. J., Sriramarao, P., et al. (1996). Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56 (17), 4032-4039.
8. Cabebe, E., and Wakelee, H. (2007). Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 8 (1), 15-27.
9. Carmeliet, P., Moons, L., Luttun, A., et al. (2001). Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 7 (5), 575-583.
10. Cohen, E. E., Rosen, L. S., Vokes, E. E., et al. (2008). Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a Phase II study. J Clin Oncol. 26 (29), 4708-4713.
11. Cohen, R. B., Kozloff, M. F., Starr, A., et al. (2007). Axitinib (AG-013736; AG) in combination with paclitaxel (P)/carboplatin (C) in patients (pts) with advanced solid tumors. Presented at the AACR-NCI-EORTC International Conference, San Francisco, California, October 22-26, Abstract A157.
12. Dutcher, J. P., Wilding, G., Hudes, G. R., et al. (2008). Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol. 26 (18S), 281s.
13. Edwards, M. P. (2008). Lipophilic efficiency (LipE) as a central concept in optimizing multiple drug properties in parallel. Personal communication.
14. Faivre, S., Demetri, G., Sargent, W., et al. (2007). Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 6 (9), 734-745.
15. Ferrara, N. (1999). Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 56 (3), 794-814.
16. Ferrara, N., Gerber, H. P., and LeCouter, J. (2003). The biology of VEGF and its receptors. Nat Med. 9 (6), 669-676.
17. Ferrara, N., Hillan, K. J., Gerber, H. P., et al. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3 (5), 391-400.
18. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med. 285 (21), 1182-1186.
19. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82 (1), 4-6.
20. Fontanini, G., Vignati, S., Boldrini, L., et al. (1997). Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res. 3 (6), 861-865.
21. Fruehauf, J. P., Lutzky, J., McDermott, D. F., et al. (2008). Axitinib (AG-013736) in patients with metastatic melanoma: a Phase II study. J Clin Oncol. 26 (15S), 484s.
22. George, D. J. (2007). Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin Cancer Res. 13 (2 Pt 2), 753s-757s.
23. Gille, H., Kowalski, J., Li, B., et al. (2001). Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 276 (5), 3222-3230.
24. Glade-Bender, J., Kandel, J. J., and Yamashiro, D. J. (2003). VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther. 3 (2), 263-276.
25. Gordon, M. S., Margolin, K., Talpaz, M., et al. (2001). Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 19 (3), 843-850.
26. Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86 (3), 353-364.
27. Hicklin, D. J., and Ellis, L. M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23 (5), 1011-1027.
28. Hopkins, A. L., Groom, C. R., and Alex, A. (2004). Ligand efficiency: a useful metric for lead selection. Drug Discov Today. 9 (10), 430-431.
29. Hubbard, S. R., Wei, L., Ellis, L., and Hendrickson, W. A. (1994). Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 372, 746-754.
30. Hu-Lowe, D., Heller, D., Brekken, J., et al. (2002). Pharmacological activities of AG013736, a small molecule inhibitor of VEGF/PDGF receptor tyrosine kinases. Presented at the 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 6-10, Abstract 5357.
31. Hu-Lowe, D. D., Zou, H. Y., Grazzini, M. L., et al. (2008). Nonclinical anti-angiogenesis and anti-tumor activity of axitinib, an oral, potent, and selective inhibitor of VEGF receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 14 (22), 7272-7283.
32. Huse, M., and Kuriyan, J. (2002). The conformational plasticity of protein kinases. Cell. 109 (3), 275-282.
33. Inai, T., Mancuso, M., Hashizume, H., et al. (2004). Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 165 (1), 35-52.
34. Jemal, A., Siegel, R., Ward, E., et al. (2007). Cancer statistics, 2007. CA Cancer J Clin. 57 (1), 43-66.
35. Jia, H., Bagherzadeh, A., Bicknell, R., et al. (2004). Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem. 279 (34), 36148-36157.
36. Jimenez, X., Lu, D., Brennan, L., et al. (2005). A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol Cancer Ther. 4 (3), 427-434.
37. Kania, R. S., Bender, S. L., and Borchardt, A. J. (2001). Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use. WO 2001/002369 A2.
38. Kaplan, R. N., Riba, R. D., Zacharoulis, S., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438 (7069), 820-827.
39. Kim, K. J., Li, B., Winer, J., et al. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362 (6423), 841-844.
40. Kuntz, I. D., Chen, K., Sharp, K. A., et al. (1999). The maximal affinity of ligands. Proc Natl Acad Sci USA. 96 (18), 9997-10002.
41. Laakkonen, P., Waltari, M., Holopainen, T., et al. (2007). Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 67 (2), 593-599.
42. Lacal, P. M., Ruffini, F., Pagani, E., et al. (2005). An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol. 27 (6), 1625-1632.
43. Mäkinen, T., Jussila, L., Veikkola, T., et al. (2001). Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 7 (2), 199-205.
44. Mancuso, M. R., Davis, R., Norberg, S. M., et al. (2006). Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 116 (10), 2610-2621.
45. Margolin, K., Gordon, M. S., Holmgren, E., et al. (2001). Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 19 (3), 851-856.
46. McTigue, M. A., Wickersham, J. A., Pinko, C., et al. (1999). Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure. 7 (3), 319-330.
47. Mol, C. D., Dougan, D. R., Schneider, T. R., et al. (2004). Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem. 279 (30), 31655-31663.
48. Morabito, A., De, M. E., Di, M. M., et al. (2006). Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions . Oncologist. 11 (7), 753-764.
49. Nagar, B., Hantschel, O., Young, M. A., et al. (2003). Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 112 (6), 859-871.
50. Pargellis, C., Tong, L., Churchill, L., et al. (2002). Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol. 9 (4), 268-272.
51. Rini, B., Wilding, G., Hudes, G., et al. (2009). Phase II study of axitinib in sorafenib -refractory metastatic renal cell carcinoma. J Clin Oncol. In press.
52. Rixe, O., Bukowski, R. M., Michaelson, M. D., et al. (2007). Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet Oncol. 8 (11), 975-984.
53. Rugo, H. S., Herbst, R. S., Liu, G., et al. (2005). Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 23 (24), 5474-5483.
54. Rugo, H. S., Stopeck, A., Joy, A. A., et al. (2007). A randomized, double-blind Phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). J Clin Oncol. 25 (18S), 32s.
55. Schiller, J. H., Larson, T., Ou, S. H. I., et al. (2009). Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a Phase II study. J Clin Oncol. In press.
56. Solowiej, J., Bergqvist, S., McTigue, M. A., et al. (2009). Characterizing the effects of the juxtamembrane domain on VEGFR2 enzymatic activity, autophosphorylation, and inhibition by axitinib. Biochemistry. In press.
57. Spano, J.-P., Chodkiewicz, C., Maurel, J., et al. (2008). Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised Phase II study. Lancet. 371 (9630), 2101-2108.
58. Su, J. L., Yen, C. J., Chen, P. S., et al. (2007). The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 96 (4), 541-545.
59. Takahashi, R., Tanaka, S., Kitadai, Y., et al. (2003). Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology. 64 (3), 266-274.
60. Tammela, T., Zarkada, G., Wallgard, E., et al. (2008). Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. doi:10.1038/nature07083.
61. Warren, R. S., Yuan, H., Matli, M. R., et al. (1995). Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 95 (4), 1789-1797.
62. Wilhelm, S., Carter, C., Lynch, M., et al. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 5 (10), 835-844.
63. Wilmes, L. J., Pallavicini, M. G., Fleming, L. M., et al. (2007). AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 25 (3), 319-327.
64. Wood, E. R., Truesdale, A. T., McDonald, O. B., et al. (2004). A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64 (2), 6652-6659.
65. Wu, Y., Hooper, A. T., Zhong, Z., et al. (2006). The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer. 119 (7), 1519-1529.
66. Yamazaki, Y., and Morita, T. (2006). Molecular and functional diversity of vascular endothelial growth factors. Mol Divers. 10 (4), 515-527.